ITC starts clinical trials for nasal spray to prevent Covid-19 infection

Sources say product is being steered by ITC Life Sciences and Technology Centre; Bengaluru. Internal trials found it to be effective against other viruses like common cold. Trials could take 3 months

ITC nasal spray

If trials show that these work in prevention, there could be several uses of such sprays – especially with schools, colleges, offices and public transport opening

Diversified conglomerate, ITC, is developing a nasal spray for Covid-19 prevention for which it has initiated clinical trials.

An ITC spokesperson confirmed the development but said, “We are unable to

Also Read

ITC Q4 consolidated net profit falls 3%, declares final dividend of Rs 5.75

Glenmark Pharmaceuticals sees potential of NONS to prevent Covid-19

ITC records sharpest intra-day gain in two months ahead of Q1 results

ITC Q2 preview: Analysts see 13% YoY revenue jump; high costs may hit PAT

Here's why CLSA is bullish on ITC; sees the stock Rs 265 levels in a year

50 medical students in Karnataka, all fully vaccinated, test Covid positive

ADB approves $1.5 bn loan to India for purchasing Covid-19 vaccines

New 'Botswana' variant is most mutated version of Covid virus: Experts

Over 18.5 lakh inoculated in MP during mega Covid-19 vaccination drive

Over 227.2 million Covid-19 vaccine doses available with States, UTs

First Published: Nov 25 2021 | 2:37 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to